[go: up one dir, main page]

MA50570A - Formulations de fulvestrant et méthodes d'utilisation de ces dernières - Google Patents

Formulations de fulvestrant et méthodes d'utilisation de ces dernières

Info

Publication number
MA50570A
MA50570A MA050570A MA50570A MA50570A MA 50570 A MA50570 A MA 50570A MA 050570 A MA050570 A MA 050570A MA 50570 A MA50570 A MA 50570A MA 50570 A MA50570 A MA 50570A
Authority
MA
Morocco
Prior art keywords
methods
fulvestrant formulations
fulvestrant
formulations
Prior art date
Application number
MA050570A
Other languages
English (en)
Inventor
Feng-Jing Chen
Adrian Hepner
Tara Jaskowski
Michael Joyce
Steven L Krill
Rama Abu Shmeis
Charles Wescott
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64650494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MA50570A publication Critical patent/MA50570A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA050570A 2017-11-08 2018-11-08 Formulations de fulvestrant et méthodes d'utilisation de ces dernières MA50570A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762583403P 2017-11-08 2017-11-08

Publications (1)

Publication Number Publication Date
MA50570A true MA50570A (fr) 2020-09-16

Family

ID=64650494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050570A MA50570A (fr) 2017-11-08 2018-11-08 Formulations de fulvestrant et méthodes d'utilisation de ces dernières

Country Status (16)

Country Link
US (1) US12186427B2 (fr)
EP (1) EP3706719A1 (fr)
JP (1) JP7220712B2 (fr)
KR (1) KR102670293B1 (fr)
CN (1) CN111479556B (fr)
AU (1) AU2018366212B2 (fr)
BR (1) BR112020009141A2 (fr)
CA (1) CA3082193A1 (fr)
CO (1) CO2020006951A2 (fr)
IL (1) IL274433B2 (fr)
MA (1) MA50570A (fr)
MX (2) MX2020004792A (fr)
MY (1) MY204442A (fr)
UA (1) UA128158C2 (fr)
WO (1) WO2019094650A1 (fr)
ZA (1) ZA202002897B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260353B (zh) * 2019-12-11 2024-11-29 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
CN120284882A (zh) * 2020-12-10 2025-07-11 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
JP2024545690A (ja) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
HUP0400115A3 (en) 2001-07-07 2005-11-28 Astrazeneca Ab Pharmaceutical composition for the intramuscular administration of fulvestrant
PL1778187T3 (pl) 2004-08-04 2012-09-28 Camurus Ab Kompozycje tworzące nielamelarne dyspersje
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
CN101244029A (zh) * 2006-03-28 2008-08-20 济南康泉医药科技有限公司 含雌激素受体拮抗剂的抗癌缓释注射剂
CN1857217A (zh) * 2006-03-28 2006-11-08 济南康泉医药科技有限公司 一种含雌激素受体拮抗剂的抗癌缓释注射剂
CA2716576A1 (fr) * 2008-03-07 2009-09-11 Nageswara R. Palepu Formulations de fulvestrant
CN101525364B (zh) 2008-03-07 2012-12-12 杭州九源基因工程有限公司 一种氟维司群的晶型及其制备方法
WO2011011978A1 (fr) * 2009-07-31 2011-02-03 西安力邦医药科技有限责任公司 Vecteur de médicament nanosphérique ou microsphérique, procédé de préparation, composition et utilisation de celui-ci
WO2011022861A1 (fr) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 Nanosphère/microsphère de fulvestrant, procédé de préparation et utilisation associés
EP2616078B1 (fr) * 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Compositions à base de fulvestrant, et procédés d'utilisation
CA2836831C (fr) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Composition pharmaceutique
CA2869377C (fr) * 2012-04-09 2022-11-08 Scidose, Llc Formulations de fulvestrant
NZ702244A (en) * 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2015003302A1 (fr) * 2013-07-08 2015-01-15 华为技术有限公司 Procédé, dispositif et système de commande pour lecture vidéo
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
JP2016529308A (ja) * 2013-09-06 2016-09-23 サラー ウッディン アハメド， フルベストラント組成物
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use

Also Published As

Publication number Publication date
IL274433A (en) 2020-06-30
RU2020118559A (ru) 2021-12-08
BR112020009141A2 (pt) 2020-10-27
MX2024010323A (es) 2025-02-10
US20230404918A1 (en) 2023-12-21
JP7220712B2 (ja) 2023-02-10
IL274433B2 (en) 2024-07-01
CO2020006951A2 (es) 2020-06-19
CN111479556A (zh) 2020-07-31
MX2020004792A (es) 2020-08-13
ZA202002897B (en) 2023-10-25
EP3706719A1 (fr) 2020-09-16
AU2018366212B2 (en) 2024-06-20
KR102670293B1 (ko) 2024-05-30
CA3082193A1 (fr) 2019-05-16
WO2019094650A1 (fr) 2019-05-16
US12186427B2 (en) 2025-01-07
KR20200085809A (ko) 2020-07-15
IL274433B1 (en) 2024-03-01
RU2020118559A3 (fr) 2021-12-08
AU2018366212A1 (en) 2020-05-14
JP2021502362A (ja) 2021-01-28
CN111479556B (zh) 2023-09-01
MY204442A (en) 2024-08-28
UA128158C2 (uk) 2024-04-24

Similar Documents

Publication Publication Date Title
MA54952A (fr) Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
EP3402549A4 (fr) Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci
EP3316880A4 (fr) Taxoïdes de troisième génération et méthodes d'utilisation de ces derniers
EP3820496A4 (fr) Constructions de fusion et leurs méthodes d'utilisation
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
EP3684361A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3735224A4 (fr) Compositions comprenant un microbiote co-sélectionné et méthodes d'utilisation de ces dernières
DK3452448T3 (da) Modulatorer af den integrerede stressvej
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EP3373969A4 (fr) Composés interagissant avec le glycane et méthodes d'utilisation
EP3615019A4 (fr) Modulateurs de l'interaction sestrine-gator2 et utilisations de ces derniers
MA44862A (fr) Formulations de fulvestrant et méthodes d'utilisation de celles-ci
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
MA53924A (fr) Modulateurs de l'expression d'apol1
EP3341218C0 (fr) Compositions de moulage et leurs méthodes d'utilisation
MA54143A (fr) Compositions et méthodes
IL268905B (en) Phage therapy
EP3373937A4 (fr) Conjugués anticorps anti-her22-maytansine et méthodes d'utilisation de ceux-ci
EP3768301A4 (fr) Compositions et méthodes d'inhibition de fas
EP3746058A4 (fr) Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane
EP3644940A4 (fr) Compositions fongicides et méthodes d'utilisation